4Gยท

๐Ÿ๐ŸŽ๐ฑ ๐†๐ž๐ง๐จ๐ฆ๐ข๐œ๐ฌ ๐๐Ÿ‘ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: ๐‘๐ž๐ฏ๐ž๐ง๐ฎ๐ž ๐†๐ซ๐จ๐ฐ๐ญ๐ก ๐’๐ญ๐š๐ฅ๐ฅ๐ฌ ๐š๐ญ ๐Ÿ%, ๐Œ๐š๐ซ๐ ๐ข๐ง๐ฌ ๐‘๐ž๐›๐จ๐ฎ๐ง๐, ๐…๐˜๐Ÿ๐Ÿ” ๐†๐ฎ๐ข๐๐š

$TXG (+0,04%)

โ €

๐Ÿ“Š ๐‘๐ž๐ฌ๐ฎ๐ฅ๐ญ๐ฌ

โ€ข Revenue: $150.7M (+1% YoY)

โ€ข GAAP EPS: -$0.15 vs. -$0.22 YoY

โ€ข Net Loss: -$19.4M vs. -$27.5M YoY

โ€ข Operating Loss: -$16.1M vs. -$32.2M YoY

โ€ข Gross Margin: 75% vs. 67% YoY (+800 bps)

โ€ข Operating Expenses: $129.0M (-3% YoY)

โ€ข Cash & Marketable Securities: $575.7M

โ €

๐ŸŽฏ ๐†๐ฎ๐ข๐๐š๐ง๐œ๐ž (๐…๐˜๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”, ๐‘๐š๐ข๐ฌ๐ž๐)

โ€ข Revenue: $625Mโ€“$635M (prior $610Mโ€“$630M)

โ€ข Revenue Growth: +4% to +6% YoY, excluding non-recurring settlement-related revenue

โ €

๐Ÿ“Œ ๐Š๐ž๐ฒ ๐“๐š๐ค๐ž๐š๐ฐ๐š๐ฒ๐ฌ

โ€ข Gross margin expanded 800 bps, primarily from lower inventory write-downs and favorable product mix

โ€ข Operating loss narrowed by approximately 50% YoY

โ€ข Began global commercial shipments of Atera, reporting strong initial customer demand

โ€ข Introduced Sentira, a cloud-based biological data analysis platform

โ€ข Sentira uses NVIDIA accelerated computing for spatial data processing and Anthropic's Claude for agentic AI analysis of single-cell data

โ€ข Nine-month revenue declined 5% to $452.5M

โ€ข Nine-month net loss widened to $50.8M from $27.3M YoY

โ€ข FY26 revenue guidance midpoint increased $10M to $630M

โ€ข Strong liquidity provides flexibility to support new product commercialization

โ €

๐Ÿ’ฌ ๐Œ๐š๐ง๐š๐ ๐ž๐ฆ๐ž๐ง๐ญ ๐‚๐จ๐ฆ๐ฆ๐ž๐ง๐ญ๐š๐ซ๐ฒ

โ€œAs biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.โ€ - CEO Serge Saxonov

1
Partecipa alla conversazione